Purpose
This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).
Materials and Methods
Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase–polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.
Results
The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926).
Conclusion
RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.
Citations
Citations to this article as recorded by
Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer Qianyi Lu, Hanxing Zhou, Jianwei Zhang, Kaping Lee, Limin Chen, Ruoxi Hong, Kuikui Jiang, Fei Xu, Wen Xia, Boyang Cao, Jingmin Zhang, Kang Shao, Peng Sun, Shusen Wang The Breast.2024; 76: 103760. CrossRef
A clinicopathologic analysis of 70 patients with mucinous breast carcinoma Rupali Sood, Karin Miller, Hua-Ling Tsai, Ashley Cimino-Mathews, Roisin M. Connolly Current Problems in Cancer: Case Reports.2024; 15: 100304. CrossRef
Clinicopathological features and prognosis of mucinous breast carcinoma with a micropapillary structure Beibei Yang, Menglu Shen, Bo Sun, Jing Zhao, Meng Wang Thoracic Cancer.2024; 15(36): 2530. CrossRef
Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States Guan-Qiao Li, Jia Yao, Ping Zhou, Dan-Xia Chen, Chen-Lu Lian, Shi-Ping Yang, Cai-Hong Huang, San-Gang Wu Clinical Breast Cancer.2022; 22(3): 279. CrossRef
Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients Yiwei Tong, Jiahui Huang, Weili Ren, Jing Yu, Xu Zhang, Zheng Wang, Jin Hong, Weiqi Gao, Jiayi Wu, Min Ji, Kunwei Shen, Xiaosong Chen European Journal of Medical Research.2022;[Epub] CrossRef
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients Peng Qi, Yu Yang, Qian-ming Bai, Tian Xue, Min Ren, Qian-lan Yao, Wen-tao Yang, Xiao-yan Zhou Breast Cancer Research and Treatment.2021; 186(2): 327. CrossRef
Oncotype DX 21‑gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma Rui Chen, Yun Wang, Taolang Li, Junyuan Lv, Guoli Feng, Na Tan, Jinjing Wang, Xiaoming Cheng Oncology Letters.2021;[Epub] CrossRef
Purpose
The purpose of this study was to investigate the changes of tumor infiltrating lymphocytes (TILs) between core needle biopsy (CNB) and surgery removed sample (SRS) in early stage breast cancer patients and to identify the correlating factors and prognostic significance of TILs changes.
Materials and Methods
A retrospective study was carried out on 255 patients who received CNB and underwent surgical resection for invasive breast cancer. Stromal TILs levels of CNB and SRS were evaluated respectively. Tumors with ≥50% stromal TILs were defined as lymphocyte-predominant breast cancer (LPBC). Clinicopathological variables were analyzed to determine whether there were factors associated with TILs changes. Log-rank tests and Cox proportional hazards models were used to analyze the influences of TILs and TILs changes on survival.
Results
SRS-TILs (median, 10.0%) were significant higher than CNB-TILs (median, 5.0%; p<0.001). Younger age (<60 years, p=0.016) and long surgery time interval (STI, ≥4 days; p=0.003) were independent factors correlating with higher TILs changes. CNB-LPBC patients showed better breast cancer-free interval (BCFI, p=0.021) than CNB-non-LPBC (CNB-nLPBC) patients. Patients were categorized into four groups according to the LPBC change pattern from CNB to SRS: LPBC→LPBC, LPBC→nLPBC, nLPBC→LPBC, and nLPBC→nLPBC, with estimated 5-year BCFI 100%, 100%, 69.7%, and 86.0% (p=0.016). nLPBC→LPBC pattern was an independent prognostic factor of worse BCFI (hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.53; p=0.035) compared with other patterns.
Conclusion
TILs were significantly higher in SRS than in CNB. Higher TILs changes were associated with younger age and long STI. Changing from nLPBC to LPBC after CNB indicated a worse BCFI, which needs further validation.
Citations
Citations to this article as recorded by
A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada Japanese Journal of Clinical Oncology.2024; 54(9): 967. CrossRef
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Janis M Taube, Brian Topp, Alexandra Snyder Journal for ImmunoTherapy of Cancer.2024; 12(7): e009427. CrossRef
Diagnostic performance of TILs–US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Erika Yokoyama, Makiko Tanaka, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Tetsuya Nakagiri, Koji Arihiro, Morihito Okada International Journal of Clinical Oncology.2024; 29(12): 1860. CrossRef
Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer Sean M. Hacking, Yihong Wang Virchows Archiv.2023; 483(6): 765. CrossRef
Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer Sean M. Hacking, Julie Karam, Kamaljeet Singh, Ece D. Gamsiz Uzun, Arlen Brickman, Evgeny Yakirevich, Ross Taliano, Yihong Wang Pathology - Research and Practice.2023; 246: 154476. CrossRef
Tumor infiltrating lymphocytes and radiological picture of the tumor Karolina Frankowska, Michał Zarobkiewicz, Izabela Dąbrowska, Agnieszka Bojarska-Junak Medical Oncology.2023;[Epub] CrossRef
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma Minna Mutka, Kristiina Joensuu, Marja Heiskala, Mine Eray, Päivi Heikkilä Virchows Archiv.2023; 483(2): 215. CrossRef
Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease Yujie Lu, Yiwei Tong, Xiaochun Fei, Xiaosong Chen, Kunwei Shen Cancer Medicine.2023; 12(15): 16264. CrossRef
Time interval between breast cancer diagnosis and surgery is associated with disease outcome Siji Zhu, Shuai Li, Jiahui Huang, Xiaochun Fei, Kunwei Shen, Xiaosong Chen Scientific Reports.2023;[Epub] CrossRef
Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer Amalia H. Landén, Kian Chin, Anikó Kovács, Erik Holmberg, Eva Molnar, Axel Stenmark Tullberg, Fredrik Wärnberg, Per Karlsson Acta Oncologica.2023; 62(12): 1862. CrossRef
Magnetic Resonance Imaging Features Associated with a High and Low Expression of Tumor-Infiltrating Lymphocytes: A Stratified Analysis According to Molecular Subtypes Jiejie Zhou, Yi Jin, Haiwei Miao, Shanshan Lu, Xinmiao Liu, Yun He, Huiru Liu, Youfan Zhao, Yang Zhang, Yan-Lin Liu, Zhifang Pan, Jeon-Hor Chen, Meihao Wang, Min-Ying Su Cancers.2023; 15(23): 5672. CrossRef
Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer Giuseppe Angelico, Giuseppe Broggi, Rosario Caltabiano, Angela Santoro, Saveria Spadola, Nicoletta D’Alessandris, Giulia Scaglione, Michele Valente, Damiano Arciuolo, Alejandro Martin Sanchez, Gianluca Franceschini, Riccardo Masetti, Antonino Mulè, Gian F Applied Sciences.2021; 11(15): 6788. CrossRef
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm npj Breast Cancer.2020;[Epub] CrossRef
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer? Alexandra Caziuc, Diana Schlanger, Giorgiana Amarinei, George Calin Dindelegan Journal of Clinical Medicine.2019; 8(4): 545. CrossRef